HALO Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals, Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 10.59%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 11.18%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 35.34%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are larger than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Halozyme Therapeutics, Inc.'s net income of $175.2M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 14.37x while ANI Pharmaceuticals, Inc.'s PE ratio is 49.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.90x versus 1.97x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 17.96%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 11.18%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $54.50 which suggests that it could fall by -0.29%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Halozyme Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.57% to investors and pays a quarterly dividend of $0.62 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 14.37x while Bristol Myers Squibb Co.'s PE ratio is 18.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.90x versus 2.30x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 21.47%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Johnson & Johnson's return on equity of 33.27%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 11.18%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.71%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics, Inc. is more attractive than Johnson & Johnson.

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 14.37x while Johnson & Johnson's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.90x versus 5.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 33.68%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Merck & Co., Inc.'s return on equity of 39.63%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 11.18%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 4.76%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Halozyme Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Halozyme Therapeutics, Inc. has a beta of 0.948, which suggesting that the stock is 5.224% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.12% to investors and pays a quarterly dividend of $0.85 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 14.37x while Merck & Co., Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 6.90x versus 4.14x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.